Form 8-K Dianthus Therapeutics, For: Mar 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
March 12, 2025 7:39 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)
The analyst comments "We are reiterating our Buy Rating on DNTH following their 4Q24 update. DNTH remains one of our favorite ideas for 2025 based on our broader view... More
